At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 719 enrolled

Drug / intervention

Ipilimumab +5 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03215706

NCT03215706Phase 3Completed

Compare CT.gov

A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Bristol-Myers Squibb·interventional·Posted Jul 12, 2017·Updated Dec 17, 2025

In Brief

A Phase 3 clinical trial evaluating Ipilimumab, Nivolumab, and 4 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 719 participants across 116 sites in 19 countries.

Detailed Summary

The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNon-Small Cell Lung Cancer

CountriesArgentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Italy, Japan, Mexico, Poland, Romania, Russia, Spain, United Kingdom, United States

Collaborators--

Timeline

Phase 3CompletedFinished

201820192020202120222023202420252026

First PostedJul 2017

Enrollment StartAug 2017

Primary CompletionAug 2019

Study CompletionOct 2024

TodayJul 2026

First PostedJul 12, 2017

Enrollment StartAug 24, 2017

Primary CompletionAug 16, 2019

Study CompletionOct 18, 2024

TodayJul 2, 2026

Enrollment to primary: 2.0 yearsPosted 9.0 years ago